Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes

Clare B. Kelly,1,2 Michelle B. Hookham,1,2 Jeremy Y. Yu,1,2 Alicia J. Jenkins,2,4 Alison J. Nankervis,5 Kristian F. Hanssen,6,7 Satish K. Garg,8 James A. Scardo,9 Samar M. Hammad,10 M. Kathryn Menard,11 Christopher E. Aston,12 and Timothy J. Lyons1,2

OBJECTIVE
This study was conducted to determine the utility of tubular (urinary/plasma neutrophil gelatinase-associated lipocalin [NGAL] and urinary kidney injury molecule 1 [KIM-1]) and glomerular (estimated glomerular filtration rate [eGFR]) biomarkers in predicting preeclampsia (PE) in pregnant women with type 1 diabetes mellitus (T1DM) who were free of microalbuminuria and hypertension at the first trimester.

RESEARCH DESIGN AND METHODS
This was a prospective study of T1DM pregnancy. Maternal urinary and plasma NGAL, urinary KIM-1 (ELISA of frozen samples), and eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) were determined at three study visits (V1: 12.4 ± 1.8; V2: 21.7 ± 1.4; V3: 31.4 ± 1.5 weeks’ gestation [mean ± SD]) in 23 women with T1DM with subsequent PE (DM+PE+), 24 who remained normotensive (DM+PE−), and, for reference, in 19 normotensive pregnant women without diabetes (DM−). The groups with diabetes were matched for age, diabetes duration, and parity. All subjects were normotensive and free of microalbuminuria or albuminuria at V1. All study visits preceded the onset of PE.

RESULTS
Urinary creatinine-corrected NGAL (uNGALcc, ng/mg) was significantly elevated at V1 in DM+PE+ vs. DM+PE− women (P = 0.01); this remained significant after exclusion of leukocyte-positive samples (5 DM+PE+ and 2 DM+PE−) (P = 0.02). Accounting for BMI, HbA1c, and total daily insulin dose, a doubling of uNGALcc at V1 conferred a sevenfold increase in risk for PE (P = 0.026). In contrast, neither plasma NGAL nor urinary KIM-1 predicted PE. Also at V1, eGFR was elevated in DM+PE+ vs. DM+PE− (P = 0.04).

CONCLUSIONS
Early tubular and glomerular dysfunction may predict PE in first trimester women with T1DM, even if free of microalbuminuria. These data suggest that subclinical renal tubular and glomerular injury, if present early in pregnancy, may predispose women with T1DM to PE.
Preeclampsia (PE) is a major cause of morbidity and mortality in pregnant women and infants. It is defined as new-onset hypertension accompanied by proteinuria (or other end-organ dysfunction) occurring after 20 weeks’ gestation in a previously normotensive woman (1). Its prevalence in the general population is 4–6% (2), but in women with pregnancy-associated type 1 diabetes mellitus (T1DM), the rate of PE is three to four times higher (3,4), even in those free of microalbuminuria early in pregnancy (5). PE is associated with maternal renal disease later in life (6,7), and in the presence of diabetes, shared features of renal disease and PE (8,9) make it difficult to decipher whether PE predisposes to renal disease or vice versa (10–13). Thus in women with T1DM, subclinical renal dysfunction, even before the onset of microalbuminuria, could predispose to PE. Biomarkers to detect such early renal damage, either tubular or glomerular, could have great clinical utility.

Human neutrophil gelatinase-associated lipocalin (NGAL) was first described as a product of activated neutrophils (14) but is now known to be widely expressed, including by infected, inflamed, or ischemic epithelia and other tissues (15–17). Its role as an early and sensitive biomarker for acute and chronic kidney disease was first described by Mishra et al. (18). Subsequent work showed NGAL is protective against ischemic and nephrotoxic injuries (19) and established its utility as a “real-time indicator of active kidney damage” (20,21); however, prospective studies to test the associations between NGAL and PE are sparse. Kidney injury molecule 1 (KIM-1) is considered a marker of renal proximal tubular damage (21) but may have less predictive power than NGAL (22,23).

Diabetes-induced changes to the glomerular vasculature play important roles in the development of albuminuria and proteinuria, and a transient elevation of the glomerular filtration rate (GFR) occurs early in the evolution of nephropathy (24). Glomerular hyperfiltration is also one of the earliest renal changes during normal pregnancy (25), but the extent of hyperfiltration, reflected by GFR early in T1DM pregnancy, might provide an early marker for PE. We investigated whether urinary NGAL (uNGAL) and/or plasma NGAL (pNGAL), urinary KIM-1, and estimated GFR (eGFR) predict subsequent PE in pregnant women with T1DM.

**Research Design and Methods**

**Study Design and Participants**

The study was approved by the Institutional Review Boards of all participating institutions, was conducted according to the principles of the Declaration of Helsinki, and was approved by the School of Medicine, Dentistry and Biomedical Sciences Ethics Committee, Queen’s University, Belfast. Written informed consent was obtained from all study participants.

Design, participants, and inclusion/exclusion criteria have been described previously (5,26,27). Briefly, 151 pregnant women with established T1DM and 24 pregnant women without diabetes were enrolled in the first trimester and monitored throughout pregnancy. Most important, all eligible enrollees were normotensive and free of microalbuminuria or overt proteinuria (i.e., urinary albumin-to-creatinine ratios were <30 mg/g at the first study visit [gestational age 9–16 weeks]). Clinical data and blood and urine samples were collected at three study visits: late first trimester (V1: gestation 12.4 ± 1.8 weeks [mean ± SD]), mid-second trimester (V2: 21.7 ± 1.4 weeks), and early third trimester (V3: 31.4 ± 1.5 weeks). Urine aliquots were stored frozen at −80°C. Serum and plasma were obtained from fasting blood samples and stored at −80°C.

PE was defined as new-onset hypertension (>140/90 mmHg) and proteinuria (>300 mg/24 h) after 20 weeks of gestation in a previously normotensive woman. For the current report, we analyzed available samples from an original total of 26 women with T1DM who developed PE (DM+PE+; n = 23; 3 lost as a result of sample attrition), from a matched group of 26 women with T1DM who remained normotensive (DM+PE--; n = 24 after attrition), and from 19 normotensive women without diabetes (DM−) to obtain reference values. The two groups with diabetes were matched as closely as possible by age, diabetes duration, HbA1c, and parity. V1 urine samples from an additional 27 unmatched DM+PE− women were subsequently added for secondary analysis to check the robustness of a logistic regression model.

Medication usage was recorded at each study visit. All patients with diabetes were taking insulin. At V1 and thereafter, most patients were taking vitamin supplements and folic acid, and their use did not differ by PE outcome or presence of diabetes. No patient was taking nonsteroidal anti-inflammatory drugs or any other potentially nephrotoxic agent. Two were taking thyroid hormone replacement. Six patients took one of the following: low-dose aspirin, cephalexin, metformin, carbamazepine, albuterol, or ondansetron.

**Laboratory Measures**

uNGAL and pNGAL (ng/mL) were measured using Human Lipocalin-2/NGAL Quantikine ELISA Kits (R&D Systems, Minneapolis, MN), according to the manufacturer’s protocols. uNGAL was creatinine corrected (uNGALcc, ng/mg). Urinary KIM-1 (ng/mL) was also measured by Quantikine ELISA (R&D Systems) and then creatinine-corrected (ng/mg). Before assay, samples were maintained frozen at −80°C from collection, and NGAL and KIM-1 detection were unaffected by freeze/thaw cycles during assay validation. The intra- and interassay coefficients of variation were 2.2% and 10.2%, respectively. Urinary creatinine was measured at University of Oklahoma Health Sciences Center Clinical Chemistry Laboratory, as previously described (5). Urinary leukocyte status was defined as positive (i.e., trace, +, ++, or ++++) or negative by Multistix 10SG urinalysis reagent strips (Siemens, Munich, Germany).

Serum creatinine was measured at the Department of Clinical Biochemistry, Royal Victoria Hospital, Belfast, Northern Ireland. eGFR was calculated at each study visit from the serum creatinine concentration, using the Chronic Kidney Disease Epidemiology Collaboration equation (28). All women had an eGFR ≥60 mL/min/1.73 m² and thus were classified as having normal renal function.

**Statistical Analysis**

Symmetrically distributed variables were summarized using mean and SD; those that were positively skewed were expressed as median (interquartile range) or geometric mean (95% CI), as appropriate. Group comparisons for categorical variables used χ² tests and independent samples t tests or Mann-Whitney tests, as appropriate, for continuous variables. Repeated measures analyses were conducted using the Friedman test. Logistic regression analysis was used to estimate the probability of women with diabetes developing PE based on clinical characteristics and biomarker values. These probabilities were used to generate receiver operating characteristic (ROC) curves, and the improvement in the area
under the curve (AUC) when biomarkers were added to clinical characteristics was assessed by the method of DeLong et al. (29). To quantify the improvement in prediction by the addition of a new biomarker, two additional novel methods were applied: the category-free net reclassification improvement (NRI) and the integrated discrimination improvement (IDI). NRI quantifies correct reclassification by counting the upward movement of predicted probabilities for patients without PE caused by the addition of a new marker to the logistic model containing only established risk factors (30). IDI compares the actual change in predicted risk in women with PE to the average decrease in predicted risk in women without PE caused by the addition of a new marker (31). All tests were two-tailed, with $P < 0.05$ considered significant. Statistical analyses were performed using SPSS 22 software (IBM Corp., Armonk, NY), Stata 13 software (StataCorp, College Station, TX), and R software (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Clinical Characteristics

Table 1 reports the baseline clinical characteristics of the three groups. Between DM+PE+ and DM+PE− groups, there were no significant differences in age, alcohol use, smoking, pregnancy outcomes (i.e., gravida, parity, abortus), age of onset and duration of T1DM, systolic and diastolic blood pressure, mean arterial pressure, total cholesterol, LDL cholesterol, triacylglycerol, microalbumin-to-creatinine ratio, and gestational age. At V1, however, BMI, HbA1c, and total daily insulin were significantly higher in DM+PE+ than in DM+PE−, and HDL cholesterol was significantly lower. There were no significant differences between DM+PE− and DM− groups at V1, except as expected, HbA1c was higher in women with diabetes.

### Table 1—Clinical characteristics at study entry

| Clinical characteristics | DM+PE+ (n = 23)       | P value* | DM+PE− (n = 24)       | P value† | DM− (n = 19)       |
|--------------------------|-----------------------|----------|-----------------------|----------|-------------------|
| Age (years)              | 28.5 ± 5.6            | 0.31     | 29.9 ± 3.8            | 0.25     | 31.4 ± 4.5        |
| BMI (kg/m²)              | 27.9 ± 5.9            | 0.03     | 24.6 ± 4.1            | 0.50     | 23.8 ± 3.8        |
| Alcohol use (%)‡         | None                  | 18.0     | 25.0                  | 0.55     | 11.0              |
|                          | None during pregnancy | 68.0     | 58.0                  |          | 68.0              |
| Smoking (%)‡             | No                    | 91.0     | 88.0                  | 0.55     | 100.0             |
|                          | Stopped in pregnancy  | 5.0      | 4.0                   |          | 0.0               |
| Pregnancy outcome        | Gravida (n)           | 1.3 ± 0.7| 1.00                  | 0.19     | 1.7 ± 1.0         |
|                          | Para (n)              | 0.2 ± 0.5| 0.91                  | 0.13     | 0.5 ± 1.0         |
|                          | Abortus (n)           | 0.1 ± 0.4| 0.91                  | 0.81     | 0.2 ± 0.4         |
| Age at onset of T1DM (years) | 11.5 ± 5.5          | 0.07     | 15.2 ± 7.5            |          | —                 |
| Duration of T1DM (years) | 16.8 ± 6.8            | 0.32     | 14.8 ± 7.0            |          | —                 |
| HbA1c (%)                | 7.4 ± 1.2             | 0.05     | 6.7 ± 1.0             | <0.0001  | 5.3 ± 0.3         |
| HbA1c (mmol/mol)         | 57 ± 14               | 0.05     | 50 ± 11               | <0.0001  | 35 ± 3            |
| Blood pressure (mmHg)    |                       |          |                       |          |                   |
|                          | Systolic              | 113.1 ± 12.4 | 0.26 | 109.4 ± 9.6 | 0.23 | 113.3 ± 8.7 |
|                          | Diastolic             | 66.6 ± 9.0 | 0.27 | 63.8 ± 8.1 | 0.24 | 66.9 ± 7.6 |
|                          | Mean arterial         | 82.1 ± 9.0 | 0.21 | 79.0 ± 7.7 | 0.14 | 82.7 ± 6.2 |
| Total daily insulin (IU/day) | 62.2 ± 19.7         | 0.01     | 47.9 ± 14.2           |          | —                 |
| Cholesterol (mmol/L)     | Total                 | 4.7 ± 0.7 | 0.53 | 4.5 ± 0.9 | 0.18 | 4.9 ± 0.7 |
|                          | HDL cholesterol       | 1.9 ± 0.4 | 0.03 | 2.2 ± 0.5 | 0.71 | 2.1 ± 0.6 |
|                          | LDL cholesterol       | 2.4 ± 0.7 | 0.08 | 2.0 ± 0.7 | 0.18 | 2.3 ± 0.8 |
|                          | Triacylglycerol (mmol/L) | 1.0 ± 0.3 | 0.27 | 0.8 ± 0.3 | 0.09 | 1.1 ± 0.4 |
|                          | Microalbumin-to-creatinine ratio (mg/g) | 5.9 (4.1, 8.7) | 0.99 | 6.3 (3.7, 8.8) | 0.40 | 7.4 (5.4, 8.7) |
| Gestational age (weeks)  | V1                    | 12.3 ± 2.1 | 0.94 | 12.3 ± 1.7 | 0.49 | 12.6 ± 1.7 |
|                          | V2                    | 22.1 ± 1.6 | 0.18 | 21.5 ± 1.3 | 0.95 | 21.5 ± 1.3 |
|                          | V3                    | 31.7 ± 1.7 | 0.39 | 31.3 ± 1.5 | 0.82 | 31.2 ± 1.1 |

Data are presented as mean ± SD or median (interquartile range). Measurements refer to V1 unless otherwise indicated. Independent samples t tests, Mann-Whitney tests, and $\chi^2$ tests were used as appropriate. $P$ values $<0.05$ (statistically significant) are highlighted in bold. *P value, DM+PE+ vs. DM+PE−. †P value, DM+PE− vs. DM−. ‡P values refer to combined percentage (i.e., “none” and “stopped during pregnancy” or “no” and “quit because of pregnancy”).
samples (i.e., 70% of diabetic and 72% of nondiabetic samples), uNGALcc remained significantly higher in DM+PE+ vs. DM+PE− at V1 (22.0 [16.3–29.6] vs. 15.0 [12.6–17.9], P = 0.02); and again, there was no difference between uNGALcc in DM+PE− (15.0 [12.6–17.9]) and DM− (15.5 [11.0–21.8]) (P = 0.852) (Fig. 1). Furthermore, with leukocyte-negative urine samples, the temporal increase in uNGALcc remained significant in the DM+PE+ group (P = 0.002), close to significant in the DM− group (P = 0.097), but was not significant for the DM+PE+ group (P = 0.135, Friedman test). None of the groups differed at V2 or V3.

pNGAL did not differ at any visit between any of the three study groups (Fig. 1C). A significant temporal increase in pNGAL with gestation was observed only in DM+PE+ women (P = 0.015).

**Urinary KIM-1**
Creatinine-corrected urinary KIM-1 did not differ at any visit between any of the three study groups (data not shown) (exclusion of leukocyte-positive samples is not relevant). Significant temporal

---

**Figure 1**—Levels of uNGALcc and pNGAL and eGFR before PE diagnosis. Longitudinal changes of uNGALcc (A), uNGALcc in leukocyte-negative samples (B), pNGAL (C), and eGFR (D) before clinical onset of PE in a prospective cohort of pregnant women. Values in A–C are the geometric mean ± 95% CI; values in D are the mean ± SEM plotted against the average gestational age at three visits. *P < 0.05 DM+PE+ vs. DM+PE−.
increases in creatinine-corrected urinary KIM-1 with gestation were observed in all three groups (P < 0.01).

eGFR

eGFR was significantly elevated at V1 in DM+PE+ vs. DM+PE− (124.2 ± 1.6 vs. 119.8 ± 1.5 mL/min/1.73 m² [mean ± SEM], P = 0.04) but did not differ at any other time point (Fig. 1D). A significant temporal decrease in eGFR with gestation was observed only in DM+PE+ women (P = 0.002). The presence of urinary leukocytes did not affect the eGFR results.

A New Model to Predict PE

To explore the significance of gestational age as an independent risk factor, we developed a mathematical model to predict PE risk before 15 weeks of gestation using readily available clinical information. To prevent confounding by NGAL derived from leukocytes, only participants with leukocyte-negative urine were included. A fixed group of covariates was selected for the model, considering group comparisons at baseline, known risk factors, and availability (i.e., clinical convenience): BMI, HbA1c, and daily total insulin dose (all continuous). After adjustment for these factors, we found that the odds of developing PE were increased sevenfold for every twofold increase in first trimester uNGALcc.

ROC curve analysis was used to assess the utility of uNGALcc to improve PE prediction based on the three clinical factors at V1 (Fig. 2 and Table 2). A model with only the clinical risk factors performed better than one using uNGALcc alone (AUC = 0.75 vs. 0.714, respectively). However, the addition of uNGALcc to the clinical risk factor model improved the predictive value (AUC = 0.849). Although this improvement did not reach statistical significance (P = 0.157), IDI and NRI results did indicate significant utility: adding uNGALcc improved discrimination between (P = 0.016) and reclassification of (P = 0.046) of women according to subsequent PE status. The final model resulted in a sensitivity of 75% and specificity of 79%.

Adjusting to account for the overall cohort prevalence (~21%), the positive predicted value was 60% and negative predictive value was 90%. In contrast, pNGAL had no predictive value (AUC = 0.546).

To test our model, we studied 27 other DM+PE− patients from our cohort (no additional DM+PE+ patients were available) who had leukocyte-negative urine samples and no evidence of urinary tract infection. uNGALcc remained significantly elevated.

| Table 2—AUC (ROC Curve), IDI, and NRI for logarithmically transformed uNGAL cc creatinine corrected [log2(uNGALcc)] and pNGAL |
| Variables per model | AUC (ROC curve) | P value | IDI score | P value | NRI score | P value |
|---------------------|----------------|---------|-----------|---------|-----------|---------|
| No variables        | 0.5            |         |           |         |           |         |
| uNGALcc only (leukocyte-negative) | 0.714         | 0.027*  |           |         |           |         |
| pNGAL only          | 0.546          | 0.590†  |           |         |           |         |
| Covariates only     | 0.744          |         |           |         |           |         |
| Covariates only (leukocyte-negative) | 0.750         |         |           |         |           |         |
| uNGALcc + covariates (leukocyte-negative) | 0.849         | 0.157†  | 0.157    | 0.016§ | 0.638     | 0.046¶ |
| pNGAL + covariates  | 0.751          | 0.419¶  | −0.002    | 0.496   | −0.190    | 0.523   |

Established risk factors (clinical covariates) were BMI, HbA1c, and total daily insulin. Bold P values are statistically significant. *AUC of “uNGALcc-only” model (leukocyte-negative) is significantly different to AUC = 0.5. †AUC of “pNGAL-only” model is not significantly different to AUC = 0.5. §uNGALcc (leukocyte-negative) improved the AUC relative to AUC of 0.750 for a logistic model containing only the covariates, although this was not significant (P = 0.157). ¶Relative to AUC of 0.744 for a logistic model containing only the covariates. §Statistically significant improvement (P = 0.016) in predicted risk of PE after the addition of uNGALcc to model with covariates only. |Statistically significant improvement (P = 0.046) in the reclassification of preeclampsia risk after the addition of uNGALcc to model with covariates only.
CONCLUSIONS

We investigated whether uNGAL and/or pNGAL, urinary KIM-1, and eGFR early in pregnancy were associated with subsequent PE in women with T1DM who were free of hypertension and microalbuminuria at study entry. This is the first simultaneous analysis of these biomarkers longitudinally in pregnancy, irrespective of diabetes or PE status. We observed a significant elevation in uNGALcc in the first trimester in DM+PE+ women compared with DM+PE− or with pregnant control subjects without diabetes. This significance was maintained when analysis was restricted to leukocyte-negative urine samples. When combined with other readily available first trimester data (BMI, HbA1c, total daily insulin dose) and in the absence of urinary leukocytes, uNGALcc remained predictive and enabled a model that predicted PE in women with T1DM (AUC = 0.849). Urinary KIM-1, in contrast, was not predictive of PE. The addition of eGFR did not alter the association of first trimester uNGALcc with PE. Nevertheless, when considered alone and at the first trimester, eGFR was positively associated with subsequent PE; however, this association was lost when covariates were also considered. In contrast to urinary levels, pNGAL levels did not show significant differences between subject groups and did not contribute to the model. It is important to note that our study was prospective and that we did not compare women with and without extant PE.

If our findings are confirmed, two very important points emerge, one of practical and the other of mechanistic value. First, uNGALcc combined with readily available clinical data may improve the early prediction of PE in women with T1DM. The ability to define which women with T1DM are at highest risk early in pregnancy would enable patient stratification for testing new interventions. Further, if one could reliably predict PE early in pregnancy, the current paradigm for pregnancy monitoring could be significantly transformed.

Second, and mechanistically, our data suggest that even before the appearance of microalbuminuria, women with T1DM who subsequently develop PE already have subclinical renal abnormalities, both tubular and glomerular (with stronger evidence for the former). Unfortunately, no prepregnancy urine samples were available to us, but it is perhaps likely that the highest-risk women had elevated uNGALcc before conception. It is also likely that as early as the first trimester, any biomarker for PE is of maternal, not placental, origin and that uNGALcc and eGFR, as early markers of maternal renal dysfunction, fall into this category.

Previous studies of uNGAL in women without diabetes, mainly reporting time points late in pregnancy, have shown no association (32,33), or a decrease (34) of uNGAL in the presence of PE. There are several possible sources for uNGAL, all potentially enhanced by diabetes: increased glomerular filtration of the small (25-kDa) protein, decreased reabsorption, or increased secretion by metabolically stressed, ischemic, or inflamed tubules, and release from neutrophils (18,19). Given the good health of our subjects with diabetes and the persistence of the first trimester association of uNGALcc with PE after exclusion of leukocyte-positive samples, we conclude that elevated urinary levels may reflect subclinical renal injury. An explanation based on glomerular leakage of a low-molecular-weight protein in the presence of early renal tubular stress is consistent with the absence of clear-cut changes in pNGAL. It is also consistent with observations (by others) that elevated uNGAL precedes microalbuminuria in developing nephropathy in nonpregnant patients with diabetes (35–38) and with the finding that proximal tubule injury precedes other conventional clinical markers of disease (39,40). These considerations provide clues to the mechanisms of PE in T1DM, and this knowledge may facilitate rational development of preventive measures in the future.

Recent studies suggest that KIM-1 has only weak prognostic value compared with NGAL to detect progression of renal disease (22,23). Our results, in the setting of PE in women with T1DM, are in concert with this conclusion. Two other studies addressed urinary KIM-1 in relation to PE. In one, KIM-1 showed no predictive ability for PE when measured at the second trimester in a general population cohort (41). In the other, KIM-1 was measured at term and was increased in women with versus without PE, but its predictive value was not addressed (42).

Pregnancy imposes a considerable burden on all aspects of renal physiology. GFR and renal blood flow both increase during gestation (43). Our finding that relatively elevated first trimester eGFR is associated with PE in the third trimester in women with T1DM is biologically plausible but will need confirmation. Increased renal ultrafiltration during pregnancy may cause tubular reabsorption overload, wherein tubules become unable to manage the filtered protein load (25). The increased eGFR may therefore contribute directly to elevated uNGAL. The data implicate both tubular and glomerular subclinical injury as harbingers of PE.

pNGAL has been studied by others in relation to PE in women without diabetes. Only two studies had longitudinal case-control designs (44,45), and these reported progressive increases in pNGAL in PE cases, with one finding a similar temporal change in normotensive pregnancy (45). In contrast to our findings, both observed elevated pNGAL throughout pregnancy in women who subsequently developed PE compared with those who did not. The discrepancy may relate to baseline differences (blood pressure and proteinuria were not clearly defined) and/or in the severity of PE. Most prior studies of pNGAL and/or uNGAL in kidney disease have addressed severe ischemic or nephrotoxic renal injury (18) and generally suggest that uNGAL is a more sensitive biomarker of renal insult than pNGAL, as reviewed by Chakraborty et al. (17). It follows that in the evolution of renal disease, changes might be expected to appear first in urine.

Our study has strengths and limitations. It is the first to longitudinally investigate uNGAL, pNGAL, urinary KIM-1, and eGFR in pregnancy complicated by PE. It
used a standardized urine collection protocol. It focuses on women with T1DM, and although this means the findings may be specific to diabetes, the high case yield may also enable efficient elucidation of markers and mechanisms for PE in the general population (women with diabetes are often excluded from studies of PE). The exclusion of women with microalbuminuria is both a strength and a limitation: it reduced the heterogeneity of an inevitably small study cohort, and in this study, enabled a focus on preclinical renal disease. The significance of the findings may extend to more slowly developing complications of diabetes, including nephropathy, where uNGALcc may also have prognostic potential. The main limitation is the small sample size. This problem has afflicted many studies of PE, and we fully endorse recent efforts to establish large international collaborations to address the disease more effectively (46).

In conclusion, uNGALcc and eGFR were elevated at the first trimester in women with T1DM who later developed PE versus those who remained normotensive. When combined with other readily available clinical data, uNGALcc enabled a model that improves the prediction of PE well before the onset of microalbuminuria or other clinical signs or symptoms. uNGALcc thus holds promise as a new marker for PE in T1DM and may enable improved management and patient stratification.

Acknowledgments. The skilled and dedicated assistance of the following individuals for the clinical components of the study is acknowledged, none of whom were compensated for their contributions: Jill Cole, Spartanburg Regional Hospital, Spartanburg, SC; Christine Knight, Jennifer Conn, Susan Hiscock, Jeremy Oats, and Peter Wein, University of Melbourne, Melbourne, Australia; and Aazar Dashti and Misti Leyva, University of Oklahoma, Oklahoma City, OK. The authors also acknowledge the scientific contributions of the following personnel, who were not compensated for their contributions: Hanne Solz and Tore Henriksen (University of Oslo), John R. Stanley (Mercy Health Center, Oklahoma City, OK), and Christopher Patterson and David McCance (Queen’s University Belfast).

Funding. This work was supported by research grants from JDRF (JDRF 1–2001–844) to T.J.L. and by National Institutes of Health (National Center for Research Resources) grants M01-RR-1070 and M01-RR-14467 to the General Clinical Research Centers at the Medical University of South Carolina and to the University of Oklahoma Health Sciences Center, respectively.

The sponsors had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Duality of Interest. This work was supported by a research grant from Novo Nordisk to T.J.L., which enabled the participation of the Barbara Davis Diabetes Center for Childhood Diabetes at the University of Colorado. No other potential conflicts of interest relevant to this article were reported.

Novo Nordisk had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Author Contributions. C.B.K., M.B.H., J.Y.Y., S.K.G., J.A.S., S.M.H., M.K.M., C.E.A., and T.J.L. contributed to acquisition, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

References. 1. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122–1131

2. Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003;41:437–445

3. Siddiqi T, Rosenn B, Mimmouni F, Khoury J, Miodovnik M. Hypertension during pregnancy in insulin-dependent diabetic women. Obstet Gynecol 1991;77:514–519

4. Hansson U, Persson B. Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity. Am J Perinatol 1993;10:330–333

5. Yu Y, Jenkins AJ, Nankervis AJ, et al. Antiangiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 2009;52:160–168

6. Vilke BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Pre-eclampsia and the risk of end-stage renal disease. N Engl J Med 2008;359:800–809

7. Chaiworapongsa T, Chaesaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014;10:466–480

8. Ekborg P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Mølvi J, Mathiesen ER. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001;24:1739–1744

9. August P. Pre-eclampsia: a “nephrocentric” view. Adv Chronic Kidney Dis 2013;20:280–286

10. Jensen DM, Damm P, Ovesen P, et al. Microalbuminuria, pre-eclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Diabetes Care 2010;33:90–94

11. Klemetti MM, Laivuori H, Tikkanen M, Nuutila M, Hilesmaa V, Teramo K. Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988–2011. Diabetologia 2015;58:678–685

12. Bramham K, Seed PT, Lightstone L, et al. Diagnnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int 2016;89:874–885

13. Kattah AG, Scantlebury DC, Agarwal S, et al. Preeclampsia and ESRD: the role of shared risk factors. Am J Kidney Dis 2017;69:498–505

14. Kjeldsen L, Johnsen AH, Sengelav H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425–10432

15. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000;1482:272–283

16. Logberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim Biophys Acta 2000;1482:284–297

17. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012;1826:129–169.

18. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534–2543

19. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:616–621

20. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007;71:967–970

21. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010;10:37–42

22. Holzschetter L, Beck C, Rutz S, et al. NGAL, L-FABP, and KIM-1 in comparison to established diagnostic and predictive biomarkers for pre-eclampsia. PLoS One 2014;9:537–546

23. Fufa GD, Weil EJ, Nelson RG, et al.; Chronic Kidney Disease Biomarkers Consortium Investigators. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015;58:188–198

24. Tomneyck J, Muskat MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017;28:1023–1039

25. Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis 2013;20:209–214

26. Du M, Basu A, Fu D, et al. Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study. Diabetes Care 2013;36:2054–2061
27. Basu A, Yu JY, Jenkins AJ, et al. Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy. Nutr Res 2015;35:421–430.

28. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55:622–627.

29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.

30. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11–21.

31. Pencina MJ, D’Agostino RB Sr, D’Agostino Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–172; discussion 207–212.

32. Ødum L, Andersen AS, Hviid TV. Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion increases in normal pregnancy but not in preeclampsia. Clin Chem Lab Med 2014;52:221–225.

33. Simonazzi G, Capelli I, Curti A, Comai G, Rizzo N, La Manna G. Serum and urinary neutrophil gelatinase-associated lipocalin monitoring in normal pregnancy versus pregnancies complicated by pre-eclampsia. In Vivo 2015;29:117–121.

34. Burwick RM, Easter SR, Dawood HY, Yamamoto HS, Fichorova RN, Feinberg BB. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension 2014;64:833–838.

35. Demir K, Abaci A, Kümé T, Altincik A, Catlı G, Böber E. Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents. J Pediatr Endocrinol Metab 2012;25:517–523.

36. Lacquaniti A, Donato V, Pintaudi B, et al. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol 2013;50:935–942.

37. Hafez MH, El-Mougy FA, Makar SH, Abd El Shaheed S. Detection of an earlier tubulopathy in diabetic nephropathy among children with normoalbuminuria. Iran J Kidney Dis 2015;9:126–131.

38. de Carvalho JA, Tatsch E, Hausen BS, et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem 2016;49:232–236.

39. Nakhoul N, Batuman V. Role of proximal tubules in the pathogenesis of kidney disease. Contrib Nephrol 2011;169:37–50.

40. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 2012;74:351–375.

41. Codsi E, Garovic VD, Gonzalez-Suarez ML, et al. Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. Am J Physiol Regul Integr Comp Physiol 2017;312:R773–R778.

42. Xiao J, Niu J, Ye X, Yu Q, Gu Y. Combined biomarkers evaluation for diagnosing kidney injury in preeclampsia. Hypertens Pregnancy 2013;32:439–449.

43. Odutayo A, Hladunewich M. Obstetric nephrology: renal hemodynamic and metabolic physiology in normal pregnancy. Clin J Am Soc Nephrol 2012;7:2073–2080.

44. D’Anna R, Baviere G, Giordano D, et al. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2010;89:275–278.

45. Karampas G, Eleftheriades M, Panoulis K, et al. Maternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate: a longitudinal study. Prenat Diagn 2014;34:726–733.

46. Roberts JM, Mascalzoni D, Ness RB, Poston L; Global Pregnancy Collaboration. Collaboration to understand complex diseases: preeclampsia and adverse pregnancy outcomes. Hypertension 2016;67:681–687.